Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000745

Drug Information
SynonymsAC1L26H7; 3-pyridinesulfonamide,N-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-; MLS001424121; CAS-56211-40-6; Luprac; MLS001195611; PW-2132; KBio2_002256; Prestwick2_001030; Torasemide N; SPBio_003080; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; Spectrum5_001699; Luprac (TN); BRN 0498515; MolPort-002-885-870; JDL 464; AC1Q6UVM; KBioGR_000820; 3-Pyridinesulfonamide, N-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-; Torocard; Torsemide [USAN]; 1-isopropyl-3-[(4- m -toluidino-3-pyridyl) sulfonyl]urea; Ambap56211-40-6; KBio3_003008; BIDD:GT0623; Unat; C16H20N4O3S; Spectrum4_000290; Demadex, Torsemide; NCGC00095141-01; TL8003646; Dilutol; Spectrum3_001832; AC 4464; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; Sutril; CID41781; BM 02015; MolPort-003-666-610; ZINC00005823; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; AC-4464; HMS1922N05; KS-1123; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; AB00514011; Torasemidum; JDL-464; GJ-1090; C026116; Toradiur; 56211-40-6; NCGC00016879-01; LS-131973; BPBio1_001341; SMR000466313; Torasemide; NCGC00095141-03; Prestwick0_001030; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; Torasemida; Spectrum_001776; Prestwick1_001030; SAM001246567; BSPBio_003503; Torasemida [INN-Spanish]; Torsemide (USP); Torem; TORSEMIDE; UNII-W31X2H97FB; BSPBio_001219; Presoril; HMS2051L21; Torasemidum [INN-Latin]; Prestwick3_001030; NCGC00095141-02; Demadex (TN); I06-0056; AC-18762; SPBio_001063; BM-02015; DB00214; N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; CHEMBL1148; CCRIS 6736; KBio2_004824; S1698_Selleck; BRD-K30480208-001-05-2; Spectrum2_001142; KBio2_007392; Torasemide (JAN/INN); Torrem; SPECTRUM1505211; KBioSS_002257; Demadex; D00382; MLS000759418; HMS1571M21; CPD000466313; MLS001165687
Trade NameDemadex
IndicationEdema associated with congestive heart failure
[ICD9: 428.0, 782.3   ICD10: I50, R60.9]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C    
Therapeutic ClassDiuretics
CAS NumberCAS 56211-40-6
PubChem Compound IDCID 41781.
PubChem Substance IDSID 182449.
SuperDrug ATC IDC03CA04
SuperDrug CAS ID056211406;
TargetSolute carrier family 12 member 1Blocker[2][3][4]
Ref 1Drug information of Torasemide, 2008 To Reference
Ref 2Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. To Reference
Ref 3Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. Nephrol Dial Transplant. 2001;16 Suppl 1:14-7. To Reference
Ref 4Hypertension. 1999 Jul;34(1):138-43.Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543